Scinopharm Taiwan, Ltd.

Scinopharm Singapore Pte Ltd.

Scniopharm Singapore Pte Ltd.

Meng-Fen Ho

Tsung-Yu Hsiao

Shu-Ping Chen

Yuan-Xiu Liao

Chia-Ning Lin

Yu-Li Lin

Julian Paul Henschke

Yung-Fa Chen

The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.

Crystalline and non-crystalline forms of SGLT2 inhibitors

New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.

Crystalline forms of docetaxel and process for preparation thereof

A process of making a polylpeptide or a pharmaceutically acceptable salt thereof comprises reacting a L-lysine protected polypeptide, which comprises L-alanine, L-tyrosine, L-glutamate, and L-lysine that is protected with a protecting group, with a tetraalkylammonium hydroxide in water to remove the protecting group.

Synthesis of glatiramer acetate

Anbydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.

Growing community of inventors

Anding, Taiwan

Meng-Fen Ho